Sign in
WithdrawnNo phase

Lafiya HIV-status Neutral Study - Protocol

Key facts

Who runs it
University of Rochester
Where
Ghana1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
20 Apr 2025
Expected to end
29 Aug 2028
Type of study
Interventional, 2 groups
Treatments tested
  • LAFIYA
Record updated
11 June 2026
Why it stopped
terminated by the new administration

Who can take part

Age
18 years to 25 years
Sex
Men only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • YGBMSM FGD and IDI: To be eligible for FGD, the person must be between 18 to 25 years old, currently identify as a cis-gender man, have had sex with another man within 8 months before engaging with the recruitment team, and must reside within a slum community in the Accra metropolitan areas. To be eligible for IDIs, participants must self-disclose living with HIV
  • GBMSM civil society organizations FGD: The person must have experience providing GBMSM with HIV prevention and care services for at least one year. Must reside in the Accra metropolitan area
  • HCF staff FGDs: HCF staff are eligible to participate in the FGDs if employed at a study-participating facility
  • Anti-ISD Trained Nurses IDIs HCF staff are eligible to participate if they are trained in our previous interventions and have previously delivered them in a Ghanaian HCF

Who cannot take part

  • YGBMSM FGD and IDI: Persons outside the age range of 18 to 25 years old, persons who do not identify as cis-gender men, persons who have not had sex with another man within 8 months before engaging with the recruitment team
  • Anti-ISD Trained Nurses IDIs: HCF staff are not eligible to participate if they are not trained in our previous interventions and have not previously delivered them in a Ghanaian HCF
  • GBMSM civil society organizations FGD: persons who do not have experience providing GBMSM with HIV prevention and care services for at least one year. Persons who do not reside within a slum community in the Accra metropolitan area (residence outside this area would be excluded)
  • HCF staff FGDs: HCF staff are not eligible to participate in the FGDs if they are not employed at a study-participating facility

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of this study is to adapt and evaluate the feasibility of "Lafiya," which means "Wellness" in Hausa, a multilevel intersectional stigma \& discrimination (ISD) and HIV testing intervention, to a status-neutral intervention to increase HIV testing, PrEP, and ART Uptake (HPART) among young gay, bisexual, and other men who have sex with men in Ghanaian slums. Specific objectives include, Assessing intersectional stigma and options for HPART implementation, Adapting Lafiya to a status-neutral intervention to address intersectional stigma and increase HPART uptake among YGBMSM, Test acceptance, feasibility, appropriateness, and preliminary efficacy of Lafiya to address intersectional stigma and increase HIVST uptake.

The 2 groups in the trial

  • Intervention ArmTreatment being tested

    Participants will be young gay, bisexual and all other men who have sex men (YGBMSM) and providers from healthcare institutions working with (YGBMSM) who will receive the LAFIYA intervention.

    Treatment: LAFIYA

  • Waitlist control group.Treatment being tested

    Control arm for comparison who will receive the intervention after the intervention group

    Treatment: LAFIYA

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Status-neutral Community-based Multilevel Intervention to Address Intersectional Stigma and Discrimination, and Increase HIV Testing, PrEP, and ART Uptake Among YGBMSM in Ghanaian Slums: A Clustered Randomized Control Trial Protocol
Publications
Record updated
11 June 2026
Lafiya HIV-status Neutral Study - Protocol (NCT06312514) – Frontlight Research